Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04956822
• Other study ID #: M2018223
• Status: Recruiting
• Start date: June 1, 2018
• Est. completion date: December 1, 2022

Study information

• Verified date: June 2021
• Source: Peking University Third Hospital
• Contact: Xiaoxuan Liu
• Phone: 13910982101
• Email: zhangys0317[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This was a cross-sectional study in which patients were divided into 20 patients with amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients with Kennedy's disease and 30 healthy controls, in which patients with amyotrophic lateral sclerosis continued to be followed up for 1 year and the results of 4 cross-sectional examinations were taken.

Description:

Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that usually starts in middle age and manifests mainly as progressive atrophy and weakness of skeletal muscles throughout the body, with death from respiratory muscle involvement after 3 to 5 years. There are no biomarkers for early diagnosis and no effective treatments. Because of the rapid progression of amyotrophic lateral sclerosis, it is important to find indicators that can objectively reflect early changes in the disease. The motor unit number index (MUNIX) is a non-invasive, rapid and objective method to assess the number of motor units, which reflects the loss of motor neurons and has its theoretical basis in monitoring early disease progression. Objective To explore the diagnostic value of MUNIX in motor neuron disease and other related disorders. To investigate the role of the 1-year rate of change of MUNIX in monitoring the disease progression in patients with amyotrophic lateral sclerosis. To investigate the role of MUNIX in predicting survival analysis of ALS patients [Design] This was a cross-sectional study in which patients were divided into 20 patients with amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients with Kennedy's disease and 30 healthy controls, in which patients with amyotrophic lateral sclerosis continued to be followed up for 1 year and the results of 4 cross-sectional examinations were taken.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 1, 2022
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• ALS patient group: 20 patients with confirmed or proposed ALS meeting the 1998 revised El Escorial diagnostic criteria for limb onset ALS.
• CMT group: 20 patients with peroneal muscular dystrophy meeting the genetically confirmed diagnosis, who signed an informed consent form.
• KD group: 20 patients with genetically confirmed Kennedy's disease consistent with genetic diagnosis, signed informed consent.
• healthy controls:

1. age-matched healthy adults who volunteered to participate;

2. definite exclusion of tremor, tonicity, and prior brain disease;

3. exclusion of common disorders affecting peripheral nerves such as entrapment peripheral neuropathy, diabetic peripheral neuropathy, and alcoholic peripheral neuropathy;

4. signed informed consent.

Exclusion Criteria:

1. signs of sensory impairment;

2. significant sphincter dysfunction;

3. visual and oculomotor impairment;

4. autonomic dysfunction;

5. signs of extravertebral symptoms;

6. severe cortical dysfunction;

7. ALS-like syndrome.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• Basic information
Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
• Functional scores
depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores

Device:
• MINUX
MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of motor unit	Motor unit estimation index (MUNIX) is a non-invasive electrophysiological technique that uses compound muscle action potential (CMAP) and surface electromyographic interference pattern (SIP) methods to evaluate the number of motor units (Mus) (motor unit number size, MUSIX).	1 year
Primary	The size of motor unit	Motor unit estimation index (MUNIX) is a non-invasive electrophysiological technique that uses compound muscle action potential (CMAP) and surface electromyographic interference pattern (SIP) methods to evaluate the number and size of motor units (Mus) (motor unit number size, MUSIX).	1 year